{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018679","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.446722+00:00","generated_at":"2026-06-08T05:20:05.692670+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Passage Bio reports Q3 net loss of $27.1M; cash runway into Q4 2025, clinical data on track","bullets":["Cash, equivalents and marketable securities of $132.8M as of Sept 30, 2023; cash runway extended into Q4 2025.","Net loss of $27.1M ($0.49 per share) for Q3 2023, comparable to $26.7M ($0.49) in Q3 2022.","R&D expenses $15.1M; G&A expenses $8.2M, down from $10.7M due to workforce reductions.","Initial safety and biomarker data from three Cohort 1 patients in PBFT02 (FTD-GRN) trial expected in Q4 2023.","GM1 trial (Imagine-1) treating multiple patients at Dose 3; initial safety/biomarker data from Dose 3 expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018679","json":"https://secwatch.observer/filing/0001558370-23-018679.json","markdown":"https://secwatch.observer/filing/0001558370-23-018679.md","text":"https://secwatch.observer/filing/0001558370-23-018679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023018679/0001558370-23-018679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023018679/pasg-20231113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:20:05.692670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c19722b71b56b7d2b73fe047ef7923be564fba4d","claim":"Passage BIO, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $27.1 million, or a net loss of $0.49 per basic and diluted share, EPS $0.49 per basic and diluted share.","evidence_excerpt":"Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023018679/0001558370-23-018679-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $27.1 million, or a net loss of $0.49 per basic and diluted share"},{"label":"EPS","value":"$0.49 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}